Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Tele2 will rebrand

4/1/24 RTKM

Bashinformsvyaz reported for 2023 by IFRS

4/1/24 BISVP

MMK reported for 2023 by RAS

4/1/24 MAGN

MD Medical Group reported for 2023 by IFRS

4/1/24 MDMG

Etalon Group expands its geographical presence

4/1/24 ETLN

Southern Kuzbass reported for 2023 by RAS

4/1/24 UKUZ

Softline reported for 2023 by IFRS

4/1/24 SOFL

UAC resumes IL-11 flight tests

4/1/24 UNAC

MFK Zaimer intends to conduct an IPO in early April

4/1/24 ZAYM

Nizhnekamskneftekhim reported for 2023 by IFRS

3/30/24 NKNC